Amanda Murphy, Ph.D., focuses her practice on strategic client counseling, portfolio management, and patent prosecution for a range of clients, including small startup companies, research foundations, and large biotechnology and pharmaceutical companies.
Amanda provides patentability opinions, prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has experience in prosecuting inter partes and ex parte reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe.
In addition to her patent counseling and prosecution practice, Amanda also routinely represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB. As part of that practice, Amanda works with experts to develop technical and legal bases for challenging or defending issued patents, and manages the preparation of substantive written submissions. She also provides strategic advice and pre-litigation analysis and prepares freedom-to-operate, enforceability, and infringement opinions.
Georgetown University Law Center
J.D., cum laude, 2010
Ph.D., Biochemistry, Molecular and Cellular Biology, 2006 Session Speech Title & Synopsis: Patent Considerations for Protein Drugs and Combination Products
Because of their complex nature, protein drugs and combination products face unique patent issues. U.S. attorneys Amanda Murphy and Michael Liu Su, from the intellectual property law firm Finnegan, will discuss key issues and recent legal developments that companies should bear in mind when seeking U.S. patents that are valid and provide sufficient scope of protection. Such issues and developments include patent eligibility, nonobviousness, and the written description and enablement requirements. For example, it is critical that companies know whether their inventions are patentable under the ever-changing legal requirement for patent eligibility, and whether their patents’ disclosures provide sufficient support for the full scope of the patent claims. This presentation will provide helpful guidance for making such determinations.